Metabolic research
Tirzepatide
Lyophilized metabolic research compound
Tirzepatide is a dual GIP / GLP-1 receptor agonist reference point in metabolic research and comparative incretin pharmacology.
This product has an available COA with reported batch details and test results.
Open available COAConfirm an optional email signup to receive a single-use 10% welcome code.
Get catalog updates仅供实验室研究使用。不适用于人类或兽医用途。并非旨在诊断、治疗、治愈、减轻或预防疾病。
Keep sealed, cold, dry, and protected from heat swings. Confirm product-specific storage on arrival.
Packed for transit stability with order support available for warm-weather routes.
Batch-linked certificate support is available through the documentation desk.
研究背景
Tirzepatide 研究资料
Tirzepatide is a dual GIP and GLP-1 receptor agonist used extensively in incretin and metabolic pharmacology research. Experimental work examines receptor activation, cyclic-AMP signaling, receptor balance, pharmacokinetics, glucose regulation, lipid markers, and downstream metabolic endpoints. It is commonly compared with GLP-1-only compounds and with newer multi-receptor molecules such as retatrutide. Buyers typically select tirzepatide when the study design specifically needs a well-characterized dual-incretin reference without glucagon-receptor activity. A large human literature exists for the pharmaceutical molecule, but those findings do not verify the composition, sterility, safety, or performance of a separate research-use product.
拟议机制
Dual agonism at GIPR and GLP-1R, two class B G-protein-coupled receptors that signal largely through cyclic AMP. Proposed effects include glucose-dependent insulin secretion, altered glucagon signaling, delayed gastric emptying through GLP-1 pathways, and central appetite-related signaling.
研究中报告的作用
- Receptor and animal studies report enhanced incretin signaling, improved glucose control, reduced food intake, and reduced body mass.
- Controlled human trials reported substantial reductions in glycated hemoglobin and body weight across studied populations.
- Frequently reported study effects include nausea, diarrhea, vomiting, constipation, and other gastrointestinal events.
常见研究终点
GIPR and GLP-1R potency, cyclic AMP, insulin and glucagon response, gastric-emptying markers, glucose, HbA1c, lipids, food intake, body mass, pharmacokinetics, and tolerability.
证据与局限
Extensive receptor, animal, and controlled human evidence exists for regulated tirzepatide products. Catalog material is not represented as equivalent to an approved pharmaceutical product.
External reading
Literature for context—not product proof.
Third-party sources describe their own research materials and methods. They do not validate a specific Azure catalog batch.
Support and documentation
Questions about this product?
What documentation can I request before ordering?
Open the available COA on this page. Before ordering, confirm the named material and listed format; when the order arrives, match the document identifiers to the supplied lot.
What should I confirm before ordering?
Compare the product name, listed amount, physical form, storage note, price, and documentation route. When the order arrives, match the product and lot or batch reference to the order record and available documentation.
Keep comparing
Compare other catalog records.
Explore related research materials. These are not a combined-use recommendation.
-
代谢 研究肽
Retatrutide
Retatrutide is a metabolic research peptide studied as a triple agonist at GIP, GLP-1, and glucagon receptors. Published studies provide receptor-pharmacology and…
- 形式
- Lyophilized powder
- 数量
- 15 mg
-
代谢 研究肽
